C16 Globotriaosyl<wbr/>ceramide-d<sub>9</sub> (d18:1/16:0-d<sub>9</sub>)

C16 Globotriaosylceramide-d9 (d18:1/16:0-d9)

CAT N°: 31199
Price:

1,274.00 1,082.90

C16 Globotriaosylceramide-d9 (d18:1/16:0-d9) is intended for use as an internal standard for the quantification of C16 globotriaosylceramide (Item No. 24875) by GC- or LC-MS. C16 Globotriaosylceramide (d18:1/16:0) is an endogenous sphingolipid found in mammalian cell membranes that is synthesized from C16 lactosylceramide (Item No. 24352).{38975} C16 Globotriaosylceramide acts as a receptor for Shiga toxin in B cell-derived Raji cells and THP-1 monocytes.{39721} It accumulates in endothelial cells, pericytes, vascular smooth muscle cells, renal epithelial cells, dorsal ganglia neuronal cells, and myocardial cells in patients with Fabry disease, a lysosomal storage disorder.{38977} Plasma levels of C16 globotriaosylceramide are increased in patients with ovarian carcinoma compared to those with benign ovarian tumors or uterine fibroids.{39712} As this product is derived from a natural source, there may be variations in the sphingoid backbone. [Matreya, LLC. Catalog No. 1551]

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N-[(1S,2R,3E)-1-[[(O-?-D-galactopyranosyl-(1?4)-O-?-D-galactopyranosyl-(1?4)-?-D-glucopyranosyl)oxy]methyl]-2-hydroxy-3-heptadecen-1-yl]-hexadecanamide-13,13,14,14,15,15,16,16,16-d9
  • Correlated keywords
    • C 16 deuterated deuterium lactosyl ceramide globotriaosyl ceramide THP1 Ceramidetrihexoside Gb 3
  • Product Overview:
    C16 Globotriaosylceramide-d9 (d18:1/16:0-d9) is intended for use as an internal standard for the quantification of C16 globotriaosylceramide (Item No. 24875) by GC- or LC-MS. C16 Globotriaosylceramide (d18:1/16:0) is an endogenous sphingolipid found in mammalian cell membranes that is synthesized from C16 lactosylceramide (Item No. 24352).{38975} C16 Globotriaosylceramide acts as a receptor for Shiga toxin in B cell-derived Raji cells and THP-1 monocytes.{39721} It accumulates in endothelial cells, pericytes, vascular smooth muscle cells, renal epithelial cells, dorsal ganglia neuronal cells, and myocardial cells in patients with Fabry disease, a lysosomal storage disorder.{38977} Plasma levels of C16 globotriaosylceramide are increased in patients with ovarian carcinoma compared to those with benign ovarian tumors or uterine fibroids.{39712} As this product is derived from a natural source, there may be variations in the sphingoid backbone. [Matreya, LLC. Catalog No. 1551]

We also advise you